Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005605 | 0.84 | KMT2A (0.68) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL9624386 | 0.84 | KMT2A (0.68) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL222373 | 0.84 | KMT2A (0.68) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL28002534 | 0.82 | KMT2A (0.66) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL30006537 | 0.82 | KMT2A (0.66) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30006002 | 0.81 | KMT2A (0.64) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30004917 | 0.81 | KMT2A (0.64) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL647372 | 0.79 | KMT2A (1.00) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 | |
| SCHEMBL16676775 | 0.79 | ALDH1A1 (0.69) | KMT2ATSHRALDH1A1POLBMEN1 | |
| SCHEMBL27468102 | 0.78 | KMT2A (0.74) | KMT2ATSHRL3MBTL1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KMT2A 1231/4885TSHR 3290/4885L3MBTL1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.